Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).

31 Finally, when Pearson's linear correlation analyses were performed between the different immunogenicity variables, positive and highly significant correlations were found, as described in the corresponding results section, demonstrating the relationship that existed between these variables, indicating that the immune response for the vaccine is not only potent in quantity but also in the quality of the antibodies elicited.

also in 132,142 other papers